March 25, 2026

How Should Biotechs Utilize Social Media for Investor Relations?

Social media sits in an awkward place for biotech investor relations. It is immediate, public, and powerful – but also informal, fast-moving, and unforgiving. Used well, it can reinforce credibility and visibility. Used poorly, it can create confusion, regulatory risk, or attract the wrong audience altogether.

The key is understanding who actually uses each platform, and for what purpose – and then being disciplined about how (and whether) you engage.

LinkedIn: the only platform that really matters for IR

If a public biotech is going to use one social platform for investor relations, it should be LinkedIn.

LinkedIn is where institutional investors, analysts, bankers, executives, and peers already spend time in a professional mindset. It is well suited to:

• Amplifying press releases.
• Promoting conference participation and webcasts.
• Sharing leadership changes or board appointments.
• Reinforcing corporate credibility.

Importantly, LinkedIn content is generally consumed more slowly and thoughtfully. That makes it a good place for factual, compliant messaging that mirrors formal disclosures.

X (formerly Twitter): for patients and advocates, not investors

X is often misunderstood by management teams. It is not an investor platform in any meaningful sense for biotech.

Where X does have value is in reaching:

• Patient communities.
• Disease advocates.
• Physicians and researchers active in specific therapeutic areas.

Tweets can be useful for corporate visibility, recruitment, or awareness  –  but they should not be confused with investor outreach. Additionally, IR teams should be cautious about using X for anything that could be construed as promotional or selective disclosure.

Instagram and Facebook: largely irrelevant

For public biotech investor relations, Instagram and Facebook simply don’t matter.

They are consumer-oriented platforms optimized for lifestyle content, not nuanced for scientific or financial communication. Time spent trying to make these channels “work” for IR is almost always time better spent elsewhere.

StockTwits: a double-edged sword

StockTwits sits somewhere between crowd-sourced fintertainment (a hybrid of finance and entertainment) and social media – and that is precisely the problem.

While it can increase visibility among retail investors, it also attracts speculation, misinformation, and momentum-driven trading. Inviting poorly informed retail interest into a biotech stock can backfire, particularly around volatile data events, since once expectations are distorted, they are hard to reset.

Most companies are better off monitoring StockTwits than actively engaging on it.

Seeking Alpha, Motley Fool and Reddit: proceed with caution

Seeking Alpha and Motley Fool can be useful, though again they are less social media and more crowd-sourced analysis. Well-informed articles can reach investors who may not read sell-side research – but commentary quality varies widely.

Reddit, by contrast, is generally too promotional, too speculative, and too difficult to control to be a productive IR channel for biotech.

The compliance overlay matters

Across all platforms, the rule is simple: social media content must be factual, non-promotional, and consistent with public disclosures. Posts should be vetted in advance by legal in exactly the same way as SEC filings and press releases.

In addition, biotech employees should be directed not to make their own independent posts about their employer, nor comment on official company posts. The risk is that they inadvertently disclose information that the company regards as confidential or has not yet chosen to make public. Instead, employees should be informed that they can – at their own discretion – repost official company posts, as well as “like” such posts on the company’s own official social media pages.